Ophthalmology and therapy · 2026
Early Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in France: A Retrospective Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fricker Jules, Sejournet Lucas, Prange Jules, Andre Julien, Calvet Remy, Rougane Valentin, Gouze Ségolène, Oudard Maxime, Ancel Ambre, Kodjikian Alexis, Nicoara Simona, Desmangles Philippe, Mathis Thibaud, Kodjikian Laurent
Аннотация
INTRODUCTION: The aim of this work is to evaluate the early real-world effectiveness, anatomical outcomes, and safety of intravitreal aflibercept 8 mg in neovascular aged-related macular degeneration (nAMD) eyes.
METHODS: This retrospective single-center study included consecutive nAMD eyes treated with at least one aflibercept 8-mg injection between January 2025 and January 2026 in France. Primary outcomes were treatment interval extension and macular drying. Secondary outcomes included changes in best-corrected visual acuity (BCVA), central macula thickness (CMT), OCT biomarkers, and safety. Subgroup analyses were performed according to treatment status, responder profile, and prior anti-VEGF generation. In addition, baseline predictive factors associated with treatment interval extension, achievement of an interval ≥ 12 weeks, and dry macular status were evaluated. A sensitivity analysis was performed in eyes with ≥ 6 months of follow-up.
RESULTS: A total of 338 eyes from 267 patients were included (82 treatment-naïve and 256 switched eyes), with a mean follow-up duration of 5.5 ± 3.3 months. In switched eyes, the mean treatment interval increased by +1.8 ± 2.4 weeks (p < 0.001), with significant gains in good responders (+ 2.7 weeks), frequent flyers (+ 0.7 weeks), and poor responders (+ 1.8 weeks) (all p < 0.001). Dry macula rates increased from 39.6% to 70.7% (p < 0.001). Among treatment-naïve eyes, 74.4% achieved a dry macula at the last visit and 97.4% at the 4-week interval following induction. In eyes with ≥ 6 months of follow-up, the interval increased by +1.6 weeks and remained significant (p < 0.001). OCT biomarkers significantly decreased during follow-up (p < 0.001), while BCVA remained stable.
CONCLUSIONS: Early real-world use of aflibercept 8 mg was associated with improved anatomical outcomes and extended treatment intervals in treatment-naïve and previously treated nAMD eyes, while maintaining stable BCVA and a favorable safety profile. These findings support its potential to reduce treatment burden in routine clinical practice.
METHODS: This retrospective single-center study included consecutive nAMD eyes treated with at least one aflibercept 8-mg injection between January 2025 and January 2026 in France. Primary outcomes were treatment interval extension and macular drying. Secondary outcomes included changes in best-corrected visual acuity (BCVA), central macula thickness (CMT), OCT biomarkers, and safety. Subgroup analyses were performed according to treatment status, responder profile, and prior anti-VEGF generation. In addition, baseline predictive factors associated with treatment interval extension, achievement of an interval ≥ 12 weeks, and dry macular status were evaluated. A sensitivity analysis was performed in eyes with ≥ 6 months of follow-up.
RESULTS: A total of 338 eyes from 267 patients were included (82 treatment-naïve and 256 switched eyes), with a mean follow-up duration of 5.5 ± 3.3 months. In switched eyes, the mean treatment interval increased by +1.8 ± 2.4 weeks (p < 0.001), with significant gains in good responders (+ 2.7 weeks), frequent flyers (+ 0.7 weeks), and poor responders (+ 1.8 weeks) (all p < 0.001). Dry macula rates increased from 39.6% to 70.7% (p < 0.001). Among treatment-naïve eyes, 74.4% achieved a dry macula at the last visit and 97.4% at the 4-week interval following induction. In eyes with ≥ 6 months of follow-up, the interval increased by +1.6 weeks and remained significant (p < 0.001). OCT biomarkers significantly decreased during follow-up (p < 0.001), while BCVA remained stable.
CONCLUSIONS: Early real-world use of aflibercept 8 mg was associated with improved anatomical outcomes and extended treatment intervals in treatment-naïve and previously treated nAMD eyes, while maintaining stable BCVA and a favorable safety profile. These findings support its potential to reduce treatment burden in routine clinical practice.